AGEN:NSD-Agenus Inc (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 5.82

Change

-0.01 (-0.17)%

Market Cap

USD 1.37B

Volume

3.96M

Avg Analyst Target

USD 12.00 (+106.19%)

Avg User Target

USD
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

Agenus Inc., a clinical-stage immuno-oncology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies. It develops vaccine programs comprising Prophage vaccine candidate; AutoSynVax, a synthetic neo-antigen; PhosPhoSynVax, a vaccine candidate to treat tumor; and QS-21 Stimulon adjuvant, a saponin-based vaccine adjuvant. The company also develops Balstilimab, an anti-PD-1 antagonist that is in Phase II clinical trial to treat second line cervical cancer; AGEN1181, an anti-CTLA-4 monospecific antibody that is in Phase 1/2 clinical trial for dose escalation study; AGEN2373, an anti-CD137 monospecific antibody that is in Phase 1 clinical trial; AGEN1223, a novel bispecific antibody to deplete regulatory T cells, which is in a Phase 1 clinical trial; AGEN-1423, a tumor microenvironment conditioning anti-CD73/TGFß TRAP bi-functional antibody that has completed Phase 1 clinical trial; AGEN1777, an anti-TIGIT bispecific antibodies; and AGEN1327, an anti-TIGIT monospecific antibody. In addition, it develops INCAGN1876, an anti-GITR monospecific antibody; INCAGN1949, an anti-OX40 monospecific antibody; INCAGN2390, an anti-TIM-3 monospecific antibody; INCAGN2385, an anti-LAG-3 monospecific antibody; and MK-4830, a monospecific antibody targeting ILT4, as well as AGENT 797, an iNKT cells that is in Phase 1 clinical trial for the treatment of COVID-19-related pneumonia; and in preclinical stage to treat multiple myeloma/B cell malignancies and solid tumors. The company has collaborations with Incyte Corporation, Merck Sharpe & Dohme, Recepta Biopharma SA, and Gilead Sciences, Inc. The company was formerly known as Antigenics Inc. and changed its name to Agenus Inc. in January 2011. Agenus Inc. was founded in 1994 and is headquartered in Lexington, Massachusetts. Address: 3 Forbes Road, Lexington, MA, United States, 02421-7305

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-09-20 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
MRNA Moderna Inc

-6.72 (-1.56%)

USD173.59B 50.81 42.25
BNTX BioNTech SE

-20.17 (-5.62%)

USD82.22B 18.72 15.10
REGN Regeneron Pharmaceuticals Inc

-10.99 (-1.69%)

USD69.72B 11.77 9.06
VRTX Vertex Pharmaceuticals Incorpo..

-2.63 (-1.40%)

USD48.85B 24.83 16.63
BGNE BeiGene Ltd

-4.64 (-1.15%)

USD42.80B N/A N/A
ALXN Alexion Pharmaceuticals Inc

N/A

USD40.34B 59.23 42.56
SGEN Seagen Inc

+2.85 (+1.82%)

USD28.42B 48.74 39.11
GMAB Genmab A/S

-0.18 (-0.42%)

USD28.19B 71.63 8.17
RPRX Royalty Pharma plc

-1.67 (-4.34%)

USD23.38B 31.17 12.50
ALNY Alnylam Pharmaceuticals Inc

-6.88 (-3.61%)

USD21.80B N/A N/A

ETFs Containing AGEN

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 83.02% 90% A- 93% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 83.02% 90% A- 93% A
Trailing 12 Months  
Capital Gain 24.36% 66% D 47% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 24.36% 66% D 45% F
Trailing 5 Years  
Capital Gain -18.03% 49% F 23% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -18.03% 49% F 21% F
Average Annual (5 Year Horizon)  
Capital Gain 6.31% 42% F 43% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 6.31% 42% F 39% F
Risk Return Profile  
Volatility (Standard Deviation) 37.07% 77% C+ 50% F
Risk Adjusted Return 17.03% 44% F 31% F
Market Capitalization 1.37B 78% C+ 70% C-
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio N/A N/A N/A N/A N/A
Price / Cash Flow Ratio -9.88 57% F 72% C-
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity N/A N/A N/A N/A N/A
Return on Invested Capital 56.72% 95% A 97% A+
Return on Assets -50.33% 12% F 4% F
Debt to Equity Ratio -8.93% 92% A- 93% A
Technical Ratios  
Short Ratio 5.75 42% F 29% F
Short Percent 11.18% 17% F 14% F
Beta 1.33 50% F 38% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date

No discussions yet

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.